Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.

JCO precision oncology - 1 Feb 2022

Garmezy Benjamin, Gheeya Jinesh, Lin Heather Y, Huang Yuefan, Kim Taebeom, Jiang Xianli, Thein Kyaw Z, Pilié Patrick G, Zeineddine Fadl, Wang Wanlin, Shaw Kenna R, Rodon Jordi, Shen John Paul, Yuan Ying, Meric-Bernstam Funda, Chen Ken, Yap Timothy A

Abstract excerpt

PURPOSE: DNA polymerase epsilon is critical to DNA proofreading and replication. Mutations in POLE have been associated with hypermutated tumors and antitumor response to immune checkpoint inhibitor (ICI) therapy. We present a clinicopathologic analysis of patients with advanced cancers harboring POLE mutations, the pattern of co-occurring mutations, and their response to ICI therapy within the context of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to DNA Polymerase II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Neoplasms

Share to Poly-ADP-Ribose Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 35108036
DOI: 10.1200/PO.21.00267
PMCID: PMC8820927

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.PMID 35108036Read ↗

Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitorSemantic proximity Read ↗

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.Semantic proximity Read ↗

Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy.Semantic proximity Read ↗

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.Semantic proximity Read ↗

The game-changing impact of POLE mutations in oncology—a review from a gynecologic oncology perspectiveSemantic proximity Read ↗

Polymerase Epsilon-Associated Ultramutagenesis in CancerSemantic proximity Read ↗

Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.Semantic proximity Read ↗

Comprehensive Analysis of Human Colorectal Cancers Harboring Polymerase Epsilon Mutations.Semantic proximity Read ↗

Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumorsSemantic proximity Read ↗

Comprehensive characterization of DNA polymerases driver variants using large genomic datasetSemantic proximity Read ↗

Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit.Semantic proximity Read ↗

Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to favorable survival of tumors with POLE mutations outside the exonuclease domainSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.